Eli Lilly and Co (LLY) Stock Price
Eli Lilly and Co Price
Revenue has compounded at 7.8% per year over the past 19 years to 65.18 B USD. Earnings per share have grown at 12.5% per year over the last 19 years. Eli Lilly and Co's net margin stands at 31.7%, up from 19.7% several years earlier. Eli Lilly and Co currently offers a dividend yield of about 0.51%. The payout ratio is around 26% of earnings. The dividend has grown at 7.2% per year over the past 19 years. Analysts set a median price target of 1,360.00 USD, implying 16.0% above the current price. Of 38 analysts, 30 rate the stock a buy — an overall Buy consensus.
Eli Lilly and Co stock price
Eli Lilly and Co business model & stock analysis
Frequently asked questions about Eli Lilly and Co
The business model of Eli Lilly and Co. revolves around research, development, and commercialization of pharmaceutical products. As one of the leading global pharmaceutical companies, Eli Lilly focuses on discovering innovative medicines to treat diseases and improve patients' lives. Through extensive research and collaboration, the company develops a wide range of therapeutic solutions across various areas such as diabetes, oncology, immunology, and neuroscience. By consistently investing in R&D, Eli Lilly strives to bring new treatments to market, ensuring quality healthcare and offering value to patients, healthcare professionals, and stakeholders worldwide.
Eli Lilly and Co is primarily active in the pharmaceutical industry.
The main competitors of Eli Lilly and Co in the market are pharmaceutical companies such as Pfizer, Johnson & Johnson, Merck & Co., Novartis, and Sanofi.
Eli Lilly and Co, founded in 1876, is a leading global pharmaceutical company headquartered in Indianapolis. With a rich history spanning over 140 years, Eli Lilly and Co has consistently focused on discovering, developing, and marketing innovative pharmaceutical products that improve people's lives. The company is committed to addressing crucial medical needs through its diverse portfolio of medicines and has made notable contributions in areas like diabetes, cancer, neuroscience, and immunology. Over the years, Eli Lilly and Co has established a strong reputation for its scientific expertise, ethical business practices, and dedication to ensuring patient safety and well-being.
Eli Lilly and Co, a renowned pharmaceutical company, has achieved significant milestones over the years. It pioneered the first commercially available insulin, revolutionizing diabetes treatment. The company also developed Prozac, a widely used antidepressant, contributing to mental health care. Eli Lilly collaboratively discovered Erbitux, an anti-cancer drug, which has transformed the treatment of colorectal cancer. Furthermore, the company introduced Humalog, a fast-acting insulin analog, enhancing diabetes management. Eli Lilly and Co has consistently demonstrated its commitment to innovation and improving patients' lives with its groundbreaking pharmaceutical developments.
Eli Lilly and Co is primarily present in various countries and regions worldwide. The company's global presence extends to markets such as the United States, Europe, Asia, and Latin America. With a strong foothold in the pharmaceutical industry, Eli Lilly and Co operates across multiple continents, including North America, where it is headquartered in Indianapolis, Indiana. Additionally, the company's international operations expand into key pharmaceutical markets like Canada, Germany, the UK, Japan, China, and Brazil. Ensuring a widespread reach, Eli Lilly and Co's presence remains significant on a global scale, contributing to its reputation as a leading pharmaceutical player.
Eli Lilly and Co is a renowned pharmaceutical company with a strong set of values and corporate philosophy. They prioritize patient well-being and improving lives through their innovative healthcare solutions. Their commitment to integrity and high ethical standards reflects in their extensive research and development efforts. Eli Lilly and Co aims to provide quality products that address unmet medical needs while fostering a culture of inclusivity and diversity within their organization. By consistently adhering to their core values, the company has become a global leader and a trustworthy partner in the pharmaceutical industry.
Analysts currently set an average price target of 1,341.63 USD for the Eli Lilly and Co stock (median: 1,360.00 USD), implying +14.0 % versus the latest price. The consensus is based on 38 analyst ratings.
38 analysts currently rate the Eli Lilly and Co stock: 30 recommend buying, 7 holding and 1 selling. For 2026, analysts expect Eli Lilly and Co to generate revenue of 88.54 B USD and earnings per share of 36.65 USD.
Converted at the current exchange rate, the Eli Lilly and Co share trades at 1,046.27 EUR (1,172.37 USD).
The Eli Lilly and Co share (LLY) is listed on 10 stock exchanges, including: NYSE (LLY), London (0Q1G.L), SIX (Zürich) (LLY.SW), XETRA (LLY.DE), Frankfurt (LLY.F), München (LLY.MU), Düsseldorf (LLY.DU), Hamburg (LLY.HM).
Eli Lilly and Co is a globally active company in the healthcare sector. Its business model focuses on developing, manufacturing, and marketing innovative drugs and healthcare products to have positive impacts on people's lives. The company operates in three main business areas: human pharmaceuticals, animal health, and biotechnology. In the field of human pharmaceuticals, the company offers a wide range of drugs for the treatment of diseases such as diabetes, cancer, arthritis, neurology, and more. Some of its well-known products include Humalog, Trulicity, Taltz, Jardiance, Forteo, and Alimta. Eli Lilly and Co is also a major player in the animal health sector, providing veterinarians and pet owners with a wide range of drugs and services. This includes specialized products for the treatment of dogs, cats, horses, cattle, pigs, and poultry. Through its biotechnology business areas, Eli Lilly and Co is also dedicated to the development of innovative therapies and technologies. It focuses on autoimmune diseases, pain management, cancer research, and affordable healthcare in emerging markets. To ensure the success of its business model, Eli Lilly and Co invests billions annually in research and development of new drugs and healthcare solutions. A significant portion of these funds goes into clinical trials to ensure the safety and efficacy of the drugs. Eli Lilly and Co intends to further expand its business by focusing on partnerships, mergers, and acquisitions to expand its portfolio and capabilities. In this context, the company has recently undertaken a number of acquisitions and partnerships, including Loxo Oncology, ImClone Systems, Sitryx, Armo BioSciences, and AC Immune. Eli Lilly and Co generates revenue worldwide by selling its products directly to retailers, collaborating closely with doctors and other medical professionals, and selling its products to wholesalers and pharmacies. The company also operates its own facilities to provide medical services and products to people and pets. In summary, Eli Lilly and Co is a leading company in the healthcare sector that aims to provide innovative and life-changing solutions for patients and pets worldwide. Through research, development, and strategic partnerships, the company has built a wide range of products and extensive expertise to effectively serve its customers and expand its presence in the global healthcare market.
The expected revenue of Eli Lilly and Co is 88.54 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Eli Lilly and Co is 32.91 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Eli Lilly and Co is currently 31.99. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Eli Lilly and Co stock.
The price-to-sales ratio (P/S) of Eli Lilly and Co is currently 11.89. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Eli Lilly and Co stock.
The Eulerpool Quality Score for Eli Lilly and Co is 7/10.
The ISIN of Eli Lilly and Co is US5324571083. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Eli Lilly and Co is 858560. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Eli Lilly and Co is LLY. The ticker symbol is used to trade Eli Lilly and Co shares on the stock exchange.
Eli Lilly and Co stock
Eli Lilly and Co Peer Group
Eli Lilly and Co Ticker
Eli Lilly and Co FIGI
All fundamentals and in-depth analysis of Eli Lilly and Co
Our stock analysis for Eli Lilly and Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eli Lilly and Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.